Alzheimer’s Therapeutics market to Cross US$ 14,856.3 Mn By 2022 - Credence Research

The latest industry report published by Credence Research, Inc. “Global Alzheimer’s Therapeutics industry – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2022,” the Alzheimer’s therapeutics industry was valued at USD 8,524.9 Mn in 2015, and is expected to reach USD 14,856.3 Mn by 2022, expanding at a CAGR of 8.02% from 2016 to 2022.

Industry Insights

Alzheimer’s disease is a progressive and currently incurable disease, and potential or supportive treatments have only emerged in the last decade. However, the currently available treatments are lacking in terms of efficacy or target-specificity. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. ACE inhibitors constitute of galantamine hydrochloride, donepezil hydrochloride and rivastigmine; NMDA receptor antagonist includes mematidine hydrochloride. Since the discovery of what plaques and tangles comprised in Alzheimer’s – amyloid β (Aβ) peptide and hyperphosphorylated tau (p-tau) protein respectively. An immense research and development has been carried out to develop therapeutics which can limit the rate of synthesis, reduce the toxicity or clear these factors from the brain. However, these attempts have been largely unsuccessful. Hence, considering the continuously rising Alzheimer prevalent population, as well as limited drugs available for treatment, Alzheimer’s disease presents a lucrative opportunity for an effective disease-modifying therapy to enter the industry.

Browse the full report Alzheimer’s Therapeutics industry – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report at http://www.credenceresearch.com/report/alzeimers-therapeutic-market

Pipeline Analysis

The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The overall pipeline for Alzeihmer’s is still very much dominated by small molecule drugs. However, there is still a considerable number of biologics in the pipeline with total 86 molecules, represented across all stages of development. According to industry experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.

Key industry Movements:

industry experts suggest that a family history of Alzheimer’s increases the risk of disease development by 7.5 times
The incidence and prevalence of Alzheimer’s disease doubles every five years after age 65 years
Currently population of developed countries is at high risk of Alzheimer due to increasing geriatric population
In developing countries from Asia Pacific and Latin America the awareness related to age-specific diseases such as dementia or Alzheimer is increasing

Request Free Sample: http://www.credenceresearch.com/sample-request/57811

Contact:

Name: Chris Smith

Designation: Global Sales Manager

E-mail: sales@credenceresearch.com

Ph: 1-800-361-8290

About Us:

Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

105 N 1st ST #429, SAN JOSE,
CA 95103, United States

This release was published on openPR.